Compare Ginkgo Bioworks Holdings Inc (DNA) vs Global E Online Ltd (GLBE) Price & Performance

Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.

The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.

GLBE trades at $38.96, up 0.67% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates, and raised its full-year outlook, with revenue growth of 39% year-over-year. Recent news includes the appointment of Tomer Gold as Chief Revenue Officer and significant insider selling by executives.

The outlook is positive with robust analyst support—93% buy ratings and a $48.86 consensus price target implying 25% upside. Key risks include insider selling pressure and execution challenges in maintaining high growth. Earnings growth and margin expansion remain primary catalysts for stock appreciation.